By altering the gut microbiota in a mice model of high-fat-diet-induced non-alcoholic fatty liver disease (NAFLD), FXR inhibition led to reduced triglyceride levels and liver lipid accumulation [38]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.